
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>Acetaminophen</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Acetaminophen which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Acetaminophen</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Acetaminophen which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Acetaminophen</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Acetaminophen which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Acetaminophen</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Acetaminophen which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Acetaminophen</td><td>Cholecalciferol</td><td>The metabolism of Acetaminophen can be decreased when combined with
Cholecalciferol.</td></tr><tr><td>Acetaminophen</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Acetaminophen which could result
in a higher serum level.</td></tr><tr><td>Acetaminophen</td><td>Rosuvastatin</td><td>The metabolism of Rosuvastatin can be increased when combined with
Acetaminophen.</td></tr><tr><td>Acetaminophen</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Acetaminophen.</td></tr><tr><td>Alendronic acid</td><td>Acetylsalicylic acid</td><td>The risk or severity of adverse effects can be increased when Acetylsalicylic
acid is combined with Alendronic acid.</td></tr><tr><td>Canrenone</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Canrenone which could
result in a higher serum level.</td></tr><tr><td>Canrenone</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Canrenone which could
result in a higher serum level.</td></tr><tr><td>Canrenone</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Canrenone which could
result in a higher serum level.</td></tr><tr><td>Canrenone</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Canrenone which could
result in a higher serum level.</td></tr><tr><td>Cobicistat</td><td>Acetaminophen</td><td>The metabolism of Acetaminophen can be decreased when combined with Cobicistat.</td></tr><tr><td>Cobicistat</td><td>Ezetimibe</td><td>Cobicistat may decrease the excretion rate of Ezetimibe which could result in a
higher serum level.</td></tr><tr><td>Cobicistat</td><td>Rosuvastatin</td><td>Cobicistat may decrease the excretion rate of Rosuvastatin which could result in
a higher serum level.</td></tr><tr><td>Cobicistat</td><td>Valsartan</td><td>The excretion of Valsartan can be decreased when combined with Cobicistat.</td></tr><tr><td>Darunavir</td><td>Acetaminophen</td><td>The metabolism of Acetaminophen can be decreased when combined with Darunavir.</td></tr><tr><td>Darunavir</td><td>Cholecalciferol</td><td>The metabolism of Cholecalciferol can be decreased when combined with Darunavir.</td></tr><tr><td>Darunavir</td><td>Ezetimibe</td><td>The excretion of Ezetimibe can be decreased when combined with Darunavir.</td></tr><tr><td>Darunavir</td><td>Pantoprazole</td><td>The metabolism of Pantoprazole can be decreased when combined with Darunavir.</td></tr><tr><td>Darunavir</td><td>Rosuvastatin</td><td>The serum concentration of Rosuvastatin can be increased when it is combined
with Darunavir.</td></tr><tr><td>Darunavir</td><td>Tramadol</td><td>The metabolism of Tramadol can be decreased when combined with Darunavir.</td></tr><tr><td>Darunavir</td><td>Valsartan</td><td>The excretion of Valsartan can be decreased when combined with Darunavir.</td></tr><tr><td>Ezetimibe</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Ezetimibe which could result in
a higher serum level.</td></tr><tr><td>Ezetimibe</td><td>Valsartan</td><td>The excretion of Ezetimibe can be decreased when combined with Valsartan.</td></tr><tr><td>Levothyroxine</td><td>Acetylsalicylic acid</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Acetylsalicylic acid.</td></tr><tr><td>Pantoprazole</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Pantoprazole which could
result in a higher serum level.</td></tr><tr><td>Pantoprazole</td><td>Alendronic acid</td><td>The therapeutic efficacy of Alendronic acid can be decreased when used in
combination with Pantoprazole.</td></tr><tr><td>Pantoprazole</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Pantoprazole which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Pantoprazole</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Pantoprazole which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Pantoprazole</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Pantoprazole which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Pantoprazole</td><td>Canrenone</td><td>Canrenone may increase the excretion rate of Pantoprazole which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Pantoprazole</td><td>Levothyroxine</td><td>Pantoprazole can cause a decrease in the absorption of Levothyroxine resulting
in a reduced serum concentration and potentially a decrease in efficacy.</td></tr><tr><td>Pantoprazole</td><td>Raltegravir</td><td>Pantoprazole can cause an increase in the absorption of Raltegravir resulting in
an increased serum concentration and potentially a worsening of adverse effects.</td></tr><tr><td>Raltegravir</td><td>Alendronic acid</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Alendronic acid is combined with Raltegravir.</td></tr><tr><td>Rosuvastatin</td><td>Alendronic acid</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Alendronic acid is combined with Rosuvastatin.</td></tr><tr><td>Rosuvastatin</td><td>Pantoprazole</td><td>The excretion of Rosuvastatin can be decreased when combined with Pantoprazole.</td></tr><tr><td>Rosuvastatin</td><td>Raltegravir</td><td>The risk or severity of myopathy and rhabdomyolysis can be increased when
Raltegravir is combined with Rosuvastatin.</td></tr><tr><td>Tenofovir alafenamide</td><td>Acetylsalicylic acid</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Acetylsalicylic acid.</td></tr><tr><td>Tenofovir alafenamide</td><td>Alendronic acid</td><td>The risk or severity of nephrotoxicity and hypocalcemia can be increased when
Tenofovir alafenamide is combined with Alendronic acid.</td></tr><tr><td>Tenofovir alafenamide</td><td>Levothyroxine</td><td>The serum concentration of Tenofovir alafenamide can be decreased when it is
combined with Levothyroxine.</td></tr><tr><td>Tenofovir alafenamide</td><td>Pantoprazole</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Pantoprazole.</td></tr><tr><td>Tenofovir alafenamide</td><td>Rosuvastatin</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Rosuvastatin.</td></tr><tr><td>Tramadol</td><td>Acetylsalicylic acid</td><td>Acetylsalicylic acid may decrease the excretion rate of Tramadol which could
result in a higher serum level.</td></tr><tr><td>Tramadol</td><td>Canrenone</td><td>The therapeutic efficacy of Canrenone can be decreased when used in combination
with Tramadol.</td></tr><tr><td>Tramadol</td><td>Canrenone</td><td>The therapeutic efficacy of Canrenone can be decreased when used in combination
with Tramadol.</td></tr><tr><td>Tramadol</td><td>Canrenone</td><td>The therapeutic efficacy of Canrenone can be decreased when used in combination
with Tramadol.</td></tr><tr><td>Tramadol</td><td>Canrenone</td><td>The therapeutic efficacy of Canrenone can be decreased when used in combination
with Tramadol.</td></tr><tr><td>Tramadol</td><td>Cholecalciferol</td><td>The metabolism of Tramadol can be decreased when combined with Cholecalciferol.</td></tr><tr><td>Tramadol</td><td>Cobicistat</td><td>The metabolism of Tramadol can be decreased when combined with Cobicistat.</td></tr><tr><td>Tramadol</td><td>Pantoprazole</td><td>Tramadol may decrease the excretion rate of Pantoprazole which could result in a
higher serum level.</td></tr><tr><td>Tramadol</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Tramadol.</td></tr><tr><td>Valsartan</td><td>Acetylsalicylic acid</td><td>The risk or severity of renal failure, hyperkalemia, and hypertension can be
increased when Valsartan is combined with Acetylsalicylic acid.</td></tr><tr><td>Valsartan</td><td>Canrenone</td><td>The risk or severity of hyperkalemia can be increased when Valsartan is combined
with Canrenone.</td></tr><tr><td>Valsartan</td><td>Canrenone</td><td>The risk or severity of hyperkalemia can be increased when Valsartan is combined
with Canrenone.</td></tr><tr><td>Valsartan</td><td>Canrenone</td><td>The risk or severity of hyperkalemia can be increased when Valsartan is combined
with Canrenone.</td></tr><tr><td>Valsartan</td><td>Canrenone</td><td>The risk or severity of hyperkalemia can be increased when Valsartan is combined
with Canrenone.</td></tr><tr><td>Valsartan</td><td>Pantoprazole</td><td>The excretion of Valsartan can be decreased when combined with Pantoprazole.</td></tr><tr><td>Valsartan</td><td>Tenofovir alafenamide</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Valsartan.</td></tr></tbody></table></div>
